Amgen’s biosimilar to Regeneron’s Eylea (aflibercept) will remain available on the US market while the two companies continue to litigate over a key patent, after the US Court of Appeals for the Federal Circuit affirmed an order denying the originator’s bid for a preliminary injunction.
The Federal Circuit in a 14 March judgment noted that Amgen’s Pavblu (aflibercept-ayyh) formulation, “while contain[ing] a version of the fusion protein aflibercept, does not contain a separate buffer component,”...